DEZHAN HEALTHCARE(SZ:000813) Zheng Quan Shi Bao Wang·2024-12-08 10:30Group 1 - The innovative drug sector saw a significant increase, closing with a rise of over 2%, with stocks like Guangshentang hitting the daily limit and others like Boteng Co. and Rejing Bio rising over 12% [1] - The National Healthcare Security Administration and the Ministry of Human Resources and Social Security released the 2024 National Basic Medical Insurance Drug List, aiming to enhance drug supply security and promote the integration of commercial health insurance with basic medical insurance [1] - Pacific Securities noted that innovative drugs are receiving more favorable treatment in medical insurance payments, with a historic high in the number and proportion of innovative drugs entering the insurance system, achieving a negotiation success rate of over 90% [1] Group 2 - Dezheng Health has the lowest price-to-book ratio among major stocks in the innovative drug sector at 1.46 times, indicating it is undervalued [2] - Dezheng Health has made significant progress in its innovative drug pipeline, including projects for cardiovascular drugs and a cannabinoid-based treatment for pulmonary hypertension, with various stages of research and development underway [2] - The company’s participation in the development of VGX-3100, a DNA nucleic acid therapy for HPV-related cervical lesions, is progressing well, with successful enrollment in phase III clinical trials [3] Group 3 - Institutional investors are increasingly recognizing Dezheng Health due to its favorable industry positioning and low valuation, as evidenced by significant share purchases by northbound funds and ETF funds [3]